We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-2.68%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.3B
AUM Growth
-$1.1B
Cap. Flow
-$283M
Cap. Flow %
-1.64%
Top 10 Hldgs %
87.61%
Holding
112
New
6
Increased
21
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$42.9M
2
ROIV icon
Roivant Sciences
ROIV
+$41.6M
3
ABCL icon
AbCellera Biologics
ABCL
+$40.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.6M
5
IMGN
Immunogen Inc
IMGN
+$17.9M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$469M
2
KYNB
Kyntra Bio
KYNB
+$39.7M
3
BPMC
Blueprint Medicines
BPMC
+$15M
4
KRYS icon
Krystal Biotech
KRYS
+$13.6M
5
VSTM icon
Verastem
VSTM
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$8.57B 49.63%
44,554,162
-2,359,607
-5% -$469M
INCY icon
2
Incyte
INCY
$25.3B
$2.25B 13.03%
36,178,056
+2,656
+0% +$178K
ONC
3
BeOne Medicines Ltd
ONC
$34.1B
$2.08B 12.04%
11,668,897
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.46B
$1.03B 5.94%
42,864,612
+926,126
+2% +$20.6M
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.5B
$357M 2.07%
1,545,113
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$330M 1.91%
3,810,248
– –
IMCR icon
7
Immunocore
IMCR
$1.68B
$151M 0.87%
2,520,731
– –
KOD icon
8
Kodiak Sciences
KOD
$2.43B
$119M 0.69%
17,310,490
– –
AKRO
9
DELISTED
Akero Therapeutics
AKRO
$111M 0.64%
2,368,378
– –
ARGX icon
10
argenx
ARGX
$55.2B
$109M 0.63%
280,159
– –
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$7.38B
$107M 0.62%
6,498,267
– –
REPL icon
12
Replimune Group
REPL
$439M
$106M 0.62%
4,578,280
– –
ABCL icon
13
AbCellera Biologics
ABCL
$1.63B
$106M 0.62%
16,450,180
+6,000,000
+57% +$40.9M
KYMR icon
14
Kymera Therapeutics
KYMR
$8.68B
$101M 0.58%
4,375,340
+1,495,515
+52% +$42.9M
ROIV icon
15
Roivant Sciences
ROIV
$23.9B
$95M 0.55%
9,428,592
+4,651,162
+97% +$41.6M
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.44B
$89.5M 0.52%
12,710,818
– –
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
$78.7M 0.46%
2,999,846
+246,344
+9% +$6.47M
TRDA icon
18
Entrada Therapeutics
TRDA
$241M
$73.7M 0.43%
4,865,819
– –
RVMD icon
19
Revolution Medicines
RVMD
$38.3B
$72M 0.42%
2,691,493
– –
IMTX icon
20
Immatics
IMTX
$1.18B
$65.1M 0.38%
5,640,816
+453,735
+9% +$4.24M
KDNY
21
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$55.9M 0.32%
1,455,202
– –
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$50.9M 0.29%
1,409,784
– –
DICE
23
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$48.1M 0.28%
1,035,786
– –
BMEA icon
24
Biomea Fusion
BMEA
$89.7M
$46.3M 0.27%
2,108,949
– –
PRLD icon
25
Prelude Therapeutics
PRLD
$360M
$45.6M 0.26%
10,123,824
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Baker Bros. Advisors held 112 positions worth $17.3B, down 6% from $18.4B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Baker Bros. Advisors's Q2 2023 filing shows 6 new, 21 increased, 12 reduced and 5 closed positions. Its largest new stake was Immunogen Inc: 1,520,097 shares worth $28.7M. The largest sale was Seagen Inc. Common Stock, an estimated $469M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2023 buy was Immunogen Inc: 1,520,097 shares worth $28.7M.
  • Baker Bros. Advisors added most to Kymera Therapeutics in Q2 2023, an estimated $42.9M increase.
  • Baker Bros. Advisors's biggest Q2 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $469M.
  • Baker Bros. Advisors fully exited Blueprint Medicines in Q2 2023, selling an estimated $15M.
  • Baker Bros. Advisors's ten largest holdings make up 88% of its $17.3B portfolio in Q2 2023.
  • Baker Bros. Advisors opened 6 new positions and closed 5 in Q2 2023.
  • Baker Bros. Advisors's portfolio value fell 6% quarter-over-quarter to $17.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.